Anti-Mouse PD-1-BX027 (RMP1-30); AlexaFluor 647-RX027

Alexa Fluor™ 647 is in the bright, far-red–fluorescent channel with an excitation max of 650 nm and an emission max of 671 nm.

Mouse PD-1 transfected BHK cells

This PhenoCycler-Fusion (CODEX)® barcoded antibody is formulated in phosphate buffered saline (150 mM NaCl) PBS, EDTA pH 7.2 containing 0.09% sodium azide as a preservative. The CODEX® reporter is lyophilized and formulated in 1X Tris-EDTA (TE) pH 8.0 (10 mM Tris-HCl, 1 mM disodium EDTA, pH 8.0)

Manufactured in an animal-free facility using only in vitro cell culture techniques, purified by affinity chromatography, and conjugated to a specific barcode under optimal conditions.

CODEX® barcoded antibody - Liquid; CODEX® reporter - Lyophilized

This PhenoCycler-Fusion (CODEX)® barcoded antibody is stable when stored at 2-8°C for up to 1 year (do not freeze). The CODEX® reporter is stable when frozen at -20°C for up to 1 year.

AB_2894157

Clone RMP1-30 recognizes an epitope on mouse PD-1.

PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.

Antibody PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

PhenoCycler-Fusion (CODEX)® reporters are made up of a fluorescent dye and a short oligonucleotide DNA barcode called a CODEX® Tag. Fluorescent reporters enable highly specific detection of corresponding barcodes, and the use of spectrally separated dyes allow for precise signal detection in up to three distinct fluorescence channels at one time.

PD-L1 (B7-H1), PD-L2

Lymphocyte clonal selection, peripheral tolerance

1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3. Honjo, T. et al. (1992) EMBO J. 11:3887.